Literature DB >> 19379636

Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.

Ming Hui Chen1.   

Abstract

Increasing use of targeted anticancer agents that inhibit tyrosine kinase signaling (monoclonal antibodies or tyrosine kinase inhibitors) has dramatically improved the survival of patients with malignancies. However, cardiotoxicity, including heart failure, left ventricular dysfunction, hypertension, myocardial infarction, and thromboembolism, has occurred. Importantly, these cardiotoxicities are at least partially reversible and responsive to medical management. Early recognition of cardiovascular side effects is vital to allow long-term, continuous therapy with these life-prolonging agents. This article reviews potential cardiovascular side effects of frequently used inhibitors of tyrosine kinase activity (eg, trastuzumab, sunitinib) and discusses the diagnosis and management of cardiotoxicity associated with targeted therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19379636     DOI： 10.1007/s11886-009-0025-9

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  50 in total

1.  Targeted cancer therapeutics: the heartbreak of success.

Authors:  Douglas L Mann
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

2.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Mechanisms of hypertension associated with BAY 43-9006.

Authors:  Maria Luisa Veronese; Ari Mosenkis; Keith T Flaherty; Maryann Gallagher; James P Stevenson; Raymond R Townsend; Peter J O'Dwyer
Journal:  J Clin Oncol       Date:  2006-01-30       Impact factor: 44.544

4.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

5.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.

Authors:  Edith A Perez; Maria Koehler; Julie Byrne; Alaknanda J Preston; Erica Rappold; Michael S Ewer
Journal:  Mayo Clin Proc       Date:  2008-06       Impact factor: 7.616

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 8.  Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.

Authors:  Ming Hui Chen; Risto Kerkelä; Thomas Force
Journal:  Circulation       Date:  2008-07-01       Impact factor: 29.690

Review 9.  Molecular basis for sunitinib efficacy and future clinical development.

Authors:  Sandrine Faivre; George Demetri; William Sargent; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

10.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Authors:  Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321
View more
  10 in total

Review 1.  Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis.

Authors:  Nadia Hedhli; Kerry Strong Russell
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

Review 2.  Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.

Authors:  Dorothy Keefe; Joanne Bowen; Rachel Gibson; Thean Tan; Meena Okera; Andrea Stringer
Journal:  Oncologist       Date:  2011-03-25

Review 3.  Kinase inhibitors and monoclonal antibodies in oncology: clinical implications.

Authors:  Helen Gharwan; Hunter Groninger
Journal:  Nat Rev Clin Oncol       Date:  2015-12-31       Impact factor: 66.675

4.  Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells.

Authors:  Anli Zhang; Hua Xue; Xiaoguang Ling; Yi Gao; Feng Yang; Liansheng Cheng; Jing Liu; Qiang Wu
Journal:  J Exp Clin Cancer Res       Date:  2010-03-10

5.  Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.

Authors:  C Porta
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

Review 6.  Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening.

Authors:  Yosuke K Kurokawa; Steven C George
Journal:  Adv Drug Deliv Rev       Date:  2015-07-23       Impact factor: 15.470

Review 7.  Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.

Authors:  Daniel J Lenihan; Peter R Kowey
Journal:  Oncologist       Date:  2013-08-05

8.  Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome.

Authors:  Nicholas G Kounis; George D Soufras; Grigorios Tsigkas; George Hahalis
Journal:  Oncoimmunology       Date:  2014-02-14       Impact factor: 8.110

9.  Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.

Authors:  Amirrtha Srikanthan; Josee-Lyne Ethier; Alberto Ocana; Bostjan Seruga; Monika K Krzyzanowska; Eitan Amir
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

10.  Liposomal TriCurin, A Synergistic Combination of Curcumin, Epicatechin Gallate and Resveratrol, Repolarizes Tumor-Associated Microglia/Macrophages, and Eliminates Glioblastoma (GBM) and GBM Stem Cells.

Authors:  Sumit Mukherjee; Juliet N E Baidoo; Samay Sampat; Andrew Mancuso; Lovena David; Leah S Cohen; Shuiqin Zhou; Probal Banerjee
Journal:  Molecules       Date:  2018-01-18       Impact factor: 4.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.